New Data Reinforce the Positive Impact of Exact Sciences’ Oncotype DX® Test on Patient Care and Healthcare Efficiency Exact Sciences, a global leader in cancer screening and diagnostic solutions, has…
Hudson Therapeutics Launches Phase 2b Part 2 Trial for NuGel Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today the initiation of Phase 2b Part 2 of its clinical trial…
Merck Opens New Facility to Boost Vaccine Production Capacity Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has officially opened a new $1 billion, 225,000-square-foot…
Pharma Industry Urges Joint Action on Growing Chronic Disease Burden Ahead of a key UN milestone, the global pharmaceutical industry has launched a Call to Action to drive collective efforts…
Noramco Invests $25M in Halo Pharma’s Whippany Facility for Sterile Injectable Manufacturing The Noramco Group, a North American provider of integrated API and drug product supply chain services, has announced…
NeoGenomics Acquires Pathline to Expand Oncology Testing in the Northeast NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing services, has announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified…
Study Confirms HER2DX® Assay’s Impact on Early-Stage HER2-Positive Breast Cancer Decisions REVEAL GENOMICS®, an innovative biotech company based in Barcelona, is excited to announce the publication of a groundbreaking study…
IMFINZI® Regimen Shows Improved Survival in Early-Stage Gastric and GEJ Cancers AstraZeneca’s innovative perioperative treatment combining IMFINZI® (durvalumab) with standard chemotherapy has shown significant improvements in survival outcomes for patients…
Scribe Therapeutics Presents Epigenetic X-Repressor Data at 2025 Keystone Symposium Scribe Therapeutics Inc. (Scribe), a leading genetic medicines company leveraging the power of CRISPR technology to transform human health, recently…
Sensorion Completes Patient Enrollment in NOTOXIS Phase 2a Trial of SENS-401 Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company focused on developing novel therapies for hearing loss, has announced the…
Sensus Healthcare to Showcase Products at AAD Annual Meeting Sensus Healthcare, Inc. (Nasdaq: SRTS), a leader in non-invasive and cost-effective treatments for skin conditions, will showcase its complete line of…
bioAffinity Technologies Plans $4 Million Cost Cut to Boost CyPath® Lung Sales bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive testing for early-stage lung cancer and…